Thyroid nodules are very common in the general population, with an estimated prevalence in the adult population of 4% as detected by palpation, 50% as detected at autopsy, and as high as 67% as detected by ultrasonography [1] . We can reasonably conclude that millions of Canadians have thyroid nodules, the vast majority of which are impalpable. With the widespread use of medical imaging, many of these nodules, some as small as 2e3 mm in diameter are detected incidentally when patients undergo imaging studies of the neck, often for reasons unrelated to the thyroid gland, hence the descriptor ''thyroid incidentalomas.'' Unless a nonpalpable thyroid nodule is causing thyrotoxicosis, its clinical significance derives from the possibility that it is an occult cancer [2] . It is thought that approximately 9%À13% of thyroid nodules, whether palpable or nonpalpable, single or multiple, are cancers [3, 4] . Most of these are welldifferentiated papillary carcinomas, the most common subtype of thyroid cancer.
In contrast to occult disease, clinically apparent thyroid cancer is not common, nor is it usually aggressive. The most recent Canadian cancer statistics estimate a 2.5% incidence of thyroid cancer in 2008, with an estimated 0.23% of all cancer deaths from this neoplasm [5] . Of the 17 types of cancer reported upon, thyroid cancer has the highest estimated 5-year survival ratio of 98%. The same document notes that the incidence rate of thyroid cancer has risen significantly over the past decade, with no change in agestandardized mortality rate, a phenomenon that the investigators acknowledge is likely because of the more frequent use of medical imaging that leads to the detection of small subclinical differentiated tumours [6] . Davies and Welch [7] , in their analysis of American data, similarly concluded that the rising incidence of thyroid cancer in the United States is attributable to increased detection of small, 10e20 mm, papillary cancers that result from increased diagnostic scrutiny, an apparent rather than a real increase in cancer incidence.
Another study from the United States showed an association between thyroid cancer incidence and socioeconomic indicators of health care access, which supports the hypothesis that the rising incidence is attributable to utilisation of new diagnostic practices rather than any real change in the epidemiology of the disease [8] . Similar trends were reported from France and Germany [9, 10] . All of these reports are highly suggestive of overdiagnosis or the detection of pseudodisease. The management of this iatrogenic epidemic of thyroid nodules has been described by 1 endocrinologist as ''the ignorant in pursuit of the impalpable'' [11] .
Autopsy studies confirm that clinically undetected thyroid cancer has a much higher prevalence than that of clinical cancer. Two such studies, 1 from Finland and 1 from Spain, demonstrated that, when the thyroid glands of persons not known to have had thyroid cancer during their lifetime were sliced into 2e3-mm blocks, 1 or more foci of occult cancer, usually of papillary origin, were detected in 36% and 22% of glands, respectively [12, 13] . Harach et al [12] calculated that, if sectioned thinly enough, virtually every Finish person's thyroid gland would be found to contain occult papillary thyroid cancer. Martinez-Tello et al [13] reasoned that most occult papillary cancers regress and that only a small number evolve into clinical cancer. Thus, there is a large reservoir of subclinical thyroid cancer in the general population, which, because of the widespread dissemination of sophisticated medical imaging technology, we now have the ability to detect.
Although it is recognized that most occult differentiated thyroid carcinomas will follow an indolent course, there are case reports from around the world of small impalpable thyroid cancers that presented with distant metastases. This has placed pressure upon physicians to investigate such nodules with ultrasound-guided fine needle aspiration (FNA). Determining when a nodule should be selected for biopsy is controversial. The work of Papini et al [14] , which recommends FNA of all 8e15 mm nodules with ''irregular margins, intranodal vascular spots, or microcalcification,'' has been influential in guiding clinical management. However, in the application of these and other sonographic characteristics reported to be predictive of thyroid cancer, Iannuccilli et al [15] concluded that only intrinsic microcalcification was a statistically significant predictor of malignancy. Moon et al [16] attributed the lack of reliability in the distinction of benign from malignant thyroid nodules based upon sonographic features to considerable overlap in their morphology, the variable experience of physicians interpreting ultrasound, technical variation in ultrasound scanners, the lack of a standard lexicon for the characterization of nodules.
For these reasons, the size of the nodule as determined by its largest diameter has become a widely used criterion for determining the need for FNA. In a recent publication, Bonavita et al [17] described 4 ultrasound patterns, which in their practice had a 100% specificity for benignity and could have obviated the need for up to 60% of biopsies. This promising observation needs to be confirmed by other workers.
The American Association of Clinical Endocrinologists (AACE), the American Thyroid Association, and the Society of Radiologists in Ultrasound (SRU) have each published practice guidelines to assist clinicians in deciding when to biopsy nonpalpable thyroid nodules [3, 4, 18] . Although there is discordance among the guidelines regarding the approach to 10-14-mm nodules, all 3 set the threshold for FNA at 10 mm in patients at low risk for thyroid cancer. The SRU guidelines are the most stringent in that a 10-mm threshold applies only if the nodule contains microcalcification ( Table 1) . McCartney and Stukenborg [19] designed a decision analysis that compares all 3 guidelines, in which the uncertain risk of delaying surgery when cancer is present was balanced with the well-defined risks of undergoing surgery for a benign asymptomatic nodule. The investigators concluded that the AACE and SRU guidelines have the best performances, depending upon which outcome is considered the less desirable: undergoing unnecessary surgery for a benign nodule or missing an early malignancy. The SRU guidelines are associated with a lower rate of surgery for benign disease, whereas the AACE guidelines yield a lower risk of missed malignancy.
The detection of cancer cells or cells with suspicious cytologic features after FNA regardless of the size of the nodule typically leads to total or partial thyroidectomy. If the excised lesion is confirmed to be malignant on histologic analysis, then adjunct radioactive iodine ablation is often performed. However, there is a substantial false positive rate associated with the cytologic assessment of thyroid nodules. Yang et al [20] , reporting on 4703 FNA samples, noted that, whereas the cytologic finding of ''positive for neoplasm'' was 98.6% predictive of histologically confirmed malignancy, the cytologic diagnosis of ''follicular neoplasm'' (which typically leads to thyroid resection) was only 32.2% predictive of malignancy. Patients undergoing treatment face the risks of thyroid surgery and perhaps a lifetime of thyroid replacement therapy and medical surveillance. They require the resources of endocrinologists, radiologists, pathologists, anesthesiologists, surgeons, nuclear medicine physicians, and various allied health professionals.
Current practice guidelines recommending FNA of small impalpable nodules create a de facto case-based screening program for a disease that, because of its low morbidity and mortality, meets none of the standard epidemiologic criteria to warrant population-based screening. Can the aggressive pursuit of occult thyroid nodules be justified in Canada when it is widely publicized that we are unable to provide timely care for large numbers of our citizens with a host of clinically apparent diseases? Our national cancer experts contradict themselves on this matter by indicating that, although the rising incidence of thyroid cancer is likely an apparent rather than a real increase, more vigilance is called for in the detection of these cancers because of this same rising incidence [5] . Their advice, if followed, will lead us into the futile cycle of increasing intervention without evidence of any population benefit [21] . It is clear that we need to gain more knowledge of the natural history of impalpable thyroid cancer, but, given the widespread dissemination of guidelines calling for FNA of small nonpalpable nodules, it is unlikely that a large randomized trial of watchful waiting vs definitive treatment will be implemented. It is interesting to note that, in a Japanese study of 162 patients with papillary microcarcinoma diagnosed by using FNA and who chose close observation rather than immediate surgery, 70% of the nodules either did not enlarge or decreased in size at a mean follow-up of 46 months [22] . It is also relevant to remember that overt differentiated papillary thyroid cancer, in particular, remains an often effectively treatable condition even when it has metastasized. Thus, the usual, if questionable, paradigm of equating the probability of cure with early diagnosis may not be valid in this circumstance.
Canada's approach to health care allocation most closely conforms to the World Medical Association models of utilitarianism, or distribution according to maximal benefit for all, and egalitarianism, or distribution according to need [23] . The utilitarian model is, in turn, based on the principle of merit, defined as the potential for individuals in society to benefit from the allocation of a resource [24] . We now have evidence that our increasingly aggressive approach to the detection of impalpable thyroid cancers has not altered the mortality rate from thyroid cancer from that era of a few decades ago in which only palpable cancers could be detected. As questioned provocatively in this context by Cronan [25] , ''is it time to turn off the ultrasound machines?''
Although such a course is unlikely, physicians who order and/or perform thyroid ultrasonography should engage in discussion both together and with patients over the merits of the aggressive pursuit of thyroid incidentalomas. In those persons discovered to have incidental nonpalpable thyroid nodules who have no clinical risk factors for thyroid cancer and no evidence of metastases, an automatic referral for FNA may not be appropriate. Individuals who are sent for FNA of subclinical impalpable thyroid nodules need to be provided with adequate information about the path upon which they are embarking. This information should include the known physical and psychological risks of treatment should their biopsy specimen demonstrate cancer cells, the possibility that they might ultimately undergo unnecessary thyroidectomy for benign disease, and a statement regarding the uncertain benefits from the treatment of potentially indolent thyroid cancer. The periodic observation of impalpable thyroid nodules in otherwise asymptomatic patients is a rational course of action [11] . In those situations in which it is deemed appropriate to proceed to FNA, the SRU guidelines would seem to be the most appropriate to apply in the Canadian context, in which medical resources are severely strained and our emphasis should be biased towards preventing unnecessary surgery for benign disease.
